AJR. American journal of roentgenology
-
AJR Am J Roentgenol · Dec 2007
Randomized Controlled Trial Multicenter StudyCT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor.
We report results from a pilot study aimed at optimizing the use of CT bidimensional measurements and 18F-FDG PET maximum standardized uptake values (SUVs-(max)) for determining response to prolonged imatinib mesylate treatment in patients with advanced gastrointestinal stromal tumors (GISTs). ⋯ The two best metrics were the optimized PET SUVmax threshold of 3.4 at 1 month (p = 0.00002) and the optimized CT bidimensional measurement threshold (no growth from baseline to 1 month, p = 0.00005) in this patient group.